
| ProKidney Corp. July 3, 2025 Page 2 | 
| ProKidney Corp. July 3, 2025 Page 3 | 
| ProKidney Corp. July 3, 2025 Page 4 | 
| A. | We have assumed that, in the case of each offering and sale of Securities (including, in the case of any offering or sale of Units, with respect to such Units and each of the Securities comprising part of such Units): | 
| (i) | the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act and, if such Securities constitute Debt Securities, the Indenture will have been qualified under the
                TIA and such effectiveness or qualification shall not have been terminated or rescinded; | 
| (ii) | a Prospectus Supplement will have been prepared and filed with the SEC describing such Securities; | 
| ProKidney Corp. July 3, 2025 Page 5 | 
| (iii) | such Securities will have been issued and sold in compliance with applicable United States federal and state securities Laws (defined below) and pursuant to and in the manner stated in the Registration Statement and the applicable
                Prospectus Supplement; | 
| (iv) | unless such Securities constitute (a) Common Stock or Debt Securities issuable upon exchange or conversion of Securities constituting Preferred Stock, (b) Common Stock or Preferred Stock issuable upon exchange or conversion of Securities
                constituting Debt Securities, (c) Common Stock, Preferred Stock or Debt Securities issuable upon exercise of Securities constituting Warrants, or (d) Common Stock, Preferred Stock or Debt Securities issuable upon exercise of Securities
                constituting Rights, a definitive purchase, underwriting or similar agreement with respect to the issuance and sale of such Securities by the Company will have been duly authorized, executed and delivered by the Company and the other
                parties thereto; | 
| (v) | at the time of the issuance of such Securities, the Company (a) will validly exist and be duly qualified and in good standing under the Laws of its jurisdiction of incorporation and (b) will have the necessary corporate power and due
                authorization, and the certificate of incorporation and bylaws of the Company will be in full force and effect and will not have been amended, restated, supplemented or otherwise altered, and there will have been no authorization of any
                such amendment, restatement, supplement or other alteration since the date hereof; | 
| (vi) | the terms of such Securities and of their issuance and sale will have been established in conformity with and so as not to violate, or result in a default under or breach of, (a) the certificate of incorporation and bylaws of the
                Company, (b) any applicable Law or any agreement or instrument binding upon the Company, (c) any requirement or restriction imposed by any court or governmental or regulatory body, including any securities exchange on which the securities
                of the Company are listed for trading, having jurisdiction over the Company and (d)(1) if such Securities constitute Preferred Stock or Debt Securities exchangeable for or convertible into, or Warrants or Rights exercisable for, Preferred
                Stock, the applicable certificate of designations and the applicable approval and authorization of the Company relating to such Preferred Stock, (2) if such Securities constitute Debt Securities or Preferred Stock exchangeable for or
                convertible into, or Warrants or Rights exercisable for, Debt Securities, the applicable Indenture and officers’ certificate or supplemental indenture and the applicable approval and authorization of the Company relating to such Debt
                Securities, (3) if such Securities constitute Warrants, the applicable Warrant Agreement therefor and the applicable approval and authorization of the Company relating to such Warrants, (4) if such Securities constitute Rights, the
                applicable Rights Agreement therefor and the applicable approval and authorization of the Company relating to such Rights, and (5) if such Securities constitute Units, the applicable Unit Agreement and the applicable approval and
                authorization of the Company relating to such Units; | 
| ProKidney Corp. July 3, 2025 Page 6 | 
| (vii) | if such Securities constitute Common Stock or Preferred Stock in respect of underlying Preferred Stock, (a) sufficient shares of Common Stock or Preferred Stock, as applicable, will be authorized for issuance under the certificate of
                incorporation of the Company that have not otherwise been issued or reserved or otherwise committed for issuance and (b) the consideration for the issuance and sale of such Common Stock or Preferred Stock established by the Board and
                provided for in the applicable definitive purchase, underwriting or similar agreement providing for the issuance and sale thereof by the Company (or, if (1) such Common Stock is issuable upon conversion of Securities constituting Preferred
                Stock, the certificate of designations therefor, (2) such Common Stock or Preferred Stock are issuable upon exchange or conversion of Securities constituting Debt Securities, the applicable Indenture and officers’ certificate or
                supplemental indenture relating to such Debt Securities, (3) such Common Stock or Preferred Stock are issuable upon exercise of Securities constituting Warrants, the applicable Warrant Agreement therefor, or (4) such Common Stock or
                Preferred Stock are issuable upon exercise of Securities constituting Rights, the applicable Rights Agreement therefor) will not be less than the par value of such Common Stock or Preferred Stock; | 
| (viii) | if (a) such Securities constitute Common Stock or Debt Securities issuable upon exchange or conversion of Securities constituting Preferred Stock, the actions with respect to such Preferred Stock referred to in paragraph 2 above will
                have been taken, (b) such Securities constitute Common Stock or Preferred Stock issuable upon exchange or conversion of Securities constituting Debt Securities, the actions with respect to Debt Securities referred to in paragraph 3 above
                will have been taken, (c) such Securities constitute Common Stock, Preferred Stock or Debt Securities issuable upon exercise of Securities constituting Warrants, the actions with respect to such Warrants referred to in paragraph 4 above
                will have been taken, or (d) such Securities constitute Common Stock, Preferred Stock or Debt Securities issuable upon exercise of Securities constituting Rights, the actions with respect to such Rights referred to in paragraph 5 above will
                have been taken; | 
| ProKidney Corp. July 3, 2025 Page 7 | 
| (ix) | if (a) such Securities constitute Preferred Stock that is exchangeable for or convertible into Securities constituting Common Stock or Debt Securities, the Company will have taken all necessary corporate action to authorize and approve
                the issuance of such Common Stock or Debt Securities upon exchange or conversion of such Preferred Stock, the terms of such exchange or conversion and related matters and, in the case of Common Stock, to reserve such Common Stock for
                issuance upon such exchange or conversion, (b) such Securities constitute Debt Securities that are exchangeable for or convertible into Securities constituting Common Stock or Preferred Stock, the Company will have then taken all corporate
                necessary action to authorize and approve the issuance of such Common Stock or Preferred Stock upon exchange or conversion of such Debt Securities (including, in the case of Preferred Stock, the filing of a certificate of designations
                respecting such Preferred Stock with the Secretary of State of the State of Delaware), the terms of such exchange or conversion and related matters and, in the case of Common Stock or Preferred Stock, to reserve such Common Stock or
                Preferred Stock for issuance upon such exchange or conversion, (c) such Securities constitute Warrants that are exercisable for Securities constituting Common Stock, Preferred Stock or Debt Securities, the Company will have taken all
                necessary corporate action to authorize and approve the issuance of such Common Stock, Preferred Stock or Debt Securities upon the exercise of such Warrants (including, in the case of Preferred Stock, the filing of a certificate of
                designations respecting such Preferred Stock with the Secretary of State of the State of Delaware), the terms of such exercise and related matters and, in the case of Common Stock or Preferred Stock, to reserve such Common Stock or
                Preferred Stock for issuance upon such exercise, (d) such Securities constitute Rights that are exercisable for Securities constituting Common Stock, Preferred Stock or Debt Securities, the Company will have taken all necessary corporate
                action to authorize and approve the issuance of such Common Stock, Preferred Stock or Debt Securities upon the exercise of such Rights (including, in the case of Preferred Stock, the filing of a certificate of designations respecting such
                Preferred Stock with the Secretary of State of the State of Delaware), the terms of such exercise and related matters and, in the case of Common Stock or Preferred Stock, to reserve such Common Stock or Preferred Stock for issuance upon
                such exercise; | 
| (x) | if such Securities constitute (or constitute Preferred Stock exchangeable for or convertible into, or Warrants or Rights exercisable for, providing for the purchase of) Debt Securities, the officers’ certificate setting forth, or
                supplemental indenture establishing, any terms of such Debt Securities different from those in the related Indenture shall not include any provision that is unenforceable against the Company; | 
| (xi) | if such Securities constitute Warrants, the Warrant Agreement related to such Warrants and not including any provision that is unenforceable against the Company will have been duly authorized, executed and delivered by the Company and a
                bank or trust company, as warrant agent, to be selected by the Company; | 
| (xii) | if such Securities constitute Rights, the Rights Agreement related to such Rights and not including any provision that is unenforceable against the Company will have been duly authorized, executed and delivered by the Company and a bank
                or trust company, as rights agent, to be selected by the Company; | 
| ProKidney Corp. July 3, 2025 Page 8 | 
| (xiii) | if such Securities constitute Units, the Unit Agreement relating to such Units and not including any provision that is unenforceable against the Company will have been duly authorized, executed and delivered by the Company and any other
                party thereto; and | 
| (xiv) | if such Securities constitute Debt Securities, Warrants, Rights or Units, the applicable Instrument and, if such Securities constitute Preferred Stock exchangeable for or convertible into, or Warrants or Rights exercisable for, Debt
                Securities, the Indenture related to such Debt Securities and, if such Securities constitute Debt Securities exchangeable for or convertible into, or Warrants or Rights exercisable for and, if such Securities constitute Units, the Unit
                Agreement related to such Units will constitute the legal, valid and binding obligation of each party thereto other than the Company, enforceable against each such party in accordance with its terms. | 
| B. | We express no opinion as to the laws of any jurisdiction other than any published constitutions, treaties, laws, rules or regulations or judicial or administrative decisions (“Laws”)
                of (i) the federal Laws of the United States; (ii) the Delaware General Corporation Law; and (iii) the Laws of the State of New York. | 
| C. | The matters expressed in this letter are subject to and qualified and limited by (i) applicable bankruptcy, insolvency, fraudulent transfer and conveyance, reorganization, moratorium and similar laws affecting creditors’ rights and
                remedies generally; (ii) general principles of equity, including without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief
                (regardless of whether considered in a proceeding in equity or at law); and (iii) securities Laws and public policy underlying such Laws with respect to rights to indemnification and contribution. | 
| Very truly yours, | |
| /s/ Akin, Gump, Strauss, Hauer & Feld LLP | |
| AKIN, GUMP, STRAUSS, HAUER & FELD LLP |